Gene therapy AMT-130 slows Huntington’s progression by 75%

SKY-0515 reduces disease-related proteins in early Huntington’s trial

Three months of daily treatment with Skyhawk Therapeutics’ oral candidate SKY-0515 safely and effectively reduced blood levels of Huntington’s disease-associated proteins in people with the neurodegenerative condition. That’s according to interim results from a substudy of a Phase 1 clinical trial that specifically showed a greater reduction with…

We’re intentionally choosing happiness while dealing with HD

When my wife, Jill, was diagnosed with Huntington’s disease (HD), our world shifted. HD is a cruel, inherited, neurodegenerative illness that affects movement, cognition, and emotions. It’s a diagnosis that forces you to confront life’s fragility head-on. For us, it also became a wake-up call — a chance to…

Eye movement could help track Huntington’s disease activity

Healthtech company Neuralight is teaming up with the CHDI Foundation to explore the possibility of monitoring eye movements as a method to track Huntington’s disease activity in clinical trials. The CHDI Foundation is a nonprofit biomedical research organization dedicated to advancing new therapies that can slow the…

Managing symptoms of Huntington’s as we transition into fall

The transition from summer into fall is beautiful, with cooler breezes, golden leaves, and cozy routines. But for someone living with Huntington’s disease, the change isn’t just about swapping flip-flops for sweaters. Seasonal shifts can bring real changes in how our bodies feel, how our moods flow, and how…

Pridopidine may slow Huntington’s progression for some patients

Pridopidine may safely and effectively slow Huntington’s disease progression in patients who aren’t taking antidopaminergic medications, which are commonly used for psychiatric symptoms and chorea, or involuntary movements. That’s according to full results from the Phase 3 PROOF-HD clinical trial  (NCT04556656), which tested pridopidine against a…